1. Home
  2. TKLF vs PCSA Comparison

TKLF vs PCSA Comparison

Compare TKLF & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yoshitsu Co. Ltd

TKLF

Yoshitsu Co. Ltd

HOLD

Current Price

$2.25

Market Cap

9.4M

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.97

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKLF
PCSA
Founded
2006
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4M
8.2M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
TKLF
PCSA
Price
$2.25
$2.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
7.3K
62.0K
Earning Date
12-19-2025
05-11-2026
Dividend Yield
10.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.95
$0.11
52 Week High
$4.32
$8.88

Technical Indicators

Market Signals
Indicator
TKLF
PCSA
Relative Strength Index (RSI) 43.83 56.24
Support Level $2.06 $2.68
Resistance Level $2.38 $3.26
Average True Range (ATR) 0.16 0.24
MACD 0.00 0.02
Stochastic Oscillator 28.09 59.57

Price Performance

Historical Comparison
TKLF
PCSA

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: